PDF(Pubmed)
Abstract：
OBJECTIVE: To explore if switching intravesical chemotherapeutic agents is beneficial in short-term recurrences of high-risk non-muscle-invasive bladder cancer (NMIBC) following the failure of preceding intravesical therapy.
METHODS: From June 2010 to October 2015, 205 patients with NMIBC who experienced tumor recurrence within a year after receiving first-line intravesical chemotherapy (IVC) were classified into two groups. After a second complete transurethral resection (TUR) process, we immediately altered the intravesical instillation agent for 107 patients (group A). In contrast, the remaining 98 patients (group B) continued using their original intravesical instillation agent. After transurethral resection of the bladder tumor (TURBT), all patients received either an immediate instillation of epirubicin (EPI), gemcitabine (GEM), or hydroxycamptothecin (HCPT), followed by regular induction and maintenance instillations. Recurrence and progression rates were evaluated using the Chi-square test, and recurrence-free survival (RFS) and progression-free survival (PFS) were calculated using the Kaplan-Meier method.
RESULTS: In this study, there was no significant difference in either the 5-year tumor recurrence or progression rates between the two groups (p > 0.05) The Kaplan-Meier plot showed no difference in progression-free or recurrence-free survival between the two groups.
CONCLUSIONS: Switching IVC agents does not improve RFS and PFS for patients with short-term recurrent high-risk NMIBC.
METHODS: From June 2010 to October 2015, 205 patients with NMIBC who experienced tumor recurrence within a year after receiving first-line intravesical chemotherapy (IVC) were classified into two groups. After a second complete transurethral resection (TUR) process, we immediately altered the intravesical instillation agent for 107 patients (group A). In contrast, the remaining 98 patients (group B) continued using their original intravesical instillation agent. After transurethral resection of the bladder tumor (TURBT), all patients received either an immediate instillation of epirubicin (EPI), gemcitabine (GEM), or hydroxycamptothecin (HCPT), followed by regular induction and maintenance instillations. Recurrence and progression rates were evaluated using the Chi-square test, and recurrence-free survival (RFS) and progression-free survival (PFS) were calculated using the Kaplan-Meier method.
RESULTS: In this study, there was no significant difference in either the 5-year tumor recurrence or progression rates between the two groups (p > 0.05) The Kaplan-Meier plot showed no difference in progression-free or recurrence-free survival between the two groups.
CONCLUSIONS: Switching IVC agents does not improve RFS and PFS for patients with short-term recurrent high-risk NMIBC.
摘要：
目的：探讨在先前的膀胱内治疗失败后，转换膀胱内化疗药物对短期复发的高风险非肌层浸润性膀胱癌（NMIBC）是否有益。
方法：2010年6月至2015年10月，205例接受一线膀胱灌注化疗（IVC）后一年内肿瘤复发的NMIBC患者分为两组。经过第二次完整的经尿道电切术（TUR），我们立即改变了107例患者的膀胱内滴注剂（A组）。相比之下,其余98例患者(B组)继续使用原来的膀胱内滴注剂.经尿道膀胱肿瘤切除术（TURBT）后，所有患者均立即滴注表柔比星（EPI），吉西他滨（GEM），或羟基喜树碱（HCPT），其次是定期诱导和维持滴注。使用卡方检验评估复发和进展率，使用Kaplan-Meier方法计算无复发生存期（RFS）和无进展生存期（PFS）。
结果：在这项研究中，两组间5年肿瘤复发率或进展率无显著差异(p>0.05),Kaplan-Meier曲线显示两组间无进展生存期或无复发生存期无显著差异.
结论：转换IVC药物不能改善短期复发性高危NMIBC患者的RFS和PFS。
方法：2010年6月至2015年10月，205例接受一线膀胱灌注化疗（IVC）后一年内肿瘤复发的NMIBC患者分为两组。经过第二次完整的经尿道电切术（TUR），我们立即改变了107例患者的膀胱内滴注剂（A组）。相比之下,其余98例患者(B组)继续使用原来的膀胱内滴注剂.经尿道膀胱肿瘤切除术（TURBT）后，所有患者均立即滴注表柔比星（EPI），吉西他滨（GEM），或羟基喜树碱（HCPT），其次是定期诱导和维持滴注。使用卡方检验评估复发和进展率，使用Kaplan-Meier方法计算无复发生存期（RFS）和无进展生存期（PFS）。
结果：在这项研究中，两组间5年肿瘤复发率或进展率无显著差异(p>0.05),Kaplan-Meier曲线显示两组间无进展生存期或无复发生存期无显著差异.
结论：转换IVC药物不能改善短期复发性高危NMIBC患者的RFS和PFS。
